|Clinical and Regulatory|
This event is set for a broad date range and therefore the exact timing is unknown. This adds a degree of risk.
|Disease and Treatment|
|Indication:||Infection Prevention in Primary Immunodeficiency Disease|
Likelihood of event success varies depending on disease, treatment and lead indication classification.
|Co. Name:||ADMA Biologics|
The OTC BB and OTC Markets have less stringent reporting and financial requirements than the NASDAQ and NYSE. This may increase the level of risk for investors. Smaller size may have an influence on likelihood of success.
Partnerships help smaller biotech companies finance the long approval process. Partnership also provides validation the clinical program may be a worthy investment.
Detailed Event Description from Company Announcement
As we continue to transition into a commercial company, with anticipated FDA approval of RI-002 during the second half of 2016, we hired key commercial staff members, procured additional raw material inventory for the future commercial production of RI-002 and continued marketing and reimbursement pre-launch activities.